Results 101 to 110 of about 104,722 (190)

Fighting viral infections and virus-driven tumors with cytotoxic CD4+ T cells [PDF]

, 2017
CD4+ T cells have been and are still largely regarded as the orchestrators of immune responses, being able to differentiate into distinct T helper cell populations based on differentiation signals, transcription factor expression, cytokine secretion, and
Adhikary, Adhikary, Adhikary, Ahn, Anderson, Annunziato, Appay, Appay, Aslan, Balfour, Battaglia, Baumjohann, Bickham, Bosselut, Britt, Brown, Brown, Brown, Brown, Brown, Bui, Cao, Cao, Cao, Carpenter, Casazza, Chen, Cheroutre, Chiu, Coler, de Souza, Deligeoroglou, Demachi-Okamura, Depil, Devarajan, Di Mitri, Dillon, Draenert, Duftner, Dumitriu, Endo, Enssle, Eshima, Facchinetti, Farrar, Faè, Fishman, Fleischer, Fontenot, Freeman, Fu, Fu, Gamadia, Gao, Garcia-Chagollan, Gasser, Geginat, Gelband, Goonetilleke, Grabowska, Grakoui, Grant, Grant, Groh, Ha, Haigh, Haque, Heaton, Hegde, Heller, Heusinkveld, Hildemann, Hislop, Hohler, Homma, Houser, Hua, Huz, Icheva, James, Jameson, Jeitziner, Johnson, Jones, Jones, Jonjic, Kadish, Kannanganat, Kaufmann, Kayagaki, Kenter, Kenter, Khanolkar, King, King, Kobayashi, Koel, Krensky, Kroesen, Kruger, Kuroda, Lazdina, Li, Libri, Lin, Loewendorf, Long, Long, Long, Long, Luckheeram, Lunemann, MacArthur, Mackay, Magnani, Malnati, Man, Manzke, Marshall, Martorelli, Mattapallil, McKinstry, McMichael, Merlo, Merlo, Metkar, Miamen, Moormann, Morales, Mosmann, Mucida, Munz, Munz, Murphy, Musey, Namekawa, Nemes, Nikiforow, Nixon, Norris, Oestreich, Omiya, O’Shea, Pachnio, Pachnio, Paludan, Pender, Peng, Penna, Piriou, Plata, Porakishvili, Qui, Quigley, Ratto-Kim, Reis, Rentenaar, Rerks-Ngarm, Ressing, Rosenberg, Sacha, Sakaguchi, Sallusto, Sandbulte, Savic, Scherrenburg, Schueller, Schulze zur Wiesch, Schulze Zur Wiesch, Schwartz, Seresini, Seresini, Soghoian, Soghoian, Spaete, Stacey, Steele, Streeck, Stuller, Su, Sun, Tagawa, Takeuchi, Tenzer, Terahara, Tewari, Thursz, Todryk, Tong, Toussirot, Trautmann, Trautmann, Trifari, Tscharke, Turnbull, Ulsenheimer, Vacchio, van de Berg, van den Hende, van Leeuwen, Vasin, Veldhoen, Ventura, Verma, Veronese, Voo, Voo, Vossen, Walker, Walton, Wang, Wang, Welters, Welters, WHO, Wilkinson, Wilson, Wilson, Wintermeyer, Workman, Xie, Xue, Yan, Yewdell, Zaunders, Zaunders, Zheng, Zhou, Zuo, zur Hausen   +229 more
core   +2 more sources

miR-196b target screen reveals mechanisms maintaining leukemia stemness with therapeutic potential. [PDF]

, 2018
We have shown that antagomiR inhibition of miRNA miR-21 and miR-196b activity is sufficient to ablate MLL-AF9 leukemia stem cells (LSC) in vivo. Here, we used an shRNA screening approach to mimic miRNA activity on experimentally verified miR-196b targets
Aronow, Bruce J., Doench, John G., Grimes, H. Leighton, Lal, Ashish, Lieberman, Judy, McGlinn, Edwina, Meyer, Sara E., Morris, Patrick J., Muench, David E., Newkold, Tess J., O\u27Brien, Eric, Orr, Emily, Perentesis, John P., Rogers, Andrew M., Salomonis, Nathan, Thomas, Craig J.   +15 more
core   +2 more sources

Studies of Tryptophans in Membrane- Spanning WALP Peptides by Deuterium NMR Spectroscopy [PDF]

, 2000
WALP pep tides of sequence acetyl-Gly-Trp-Trp-(Leu-Ala)-Trp-Trp-Ala-ethanolamine insert into lipid bilayers as membrane-spanning a-helices and modulate the lipid phase behavior as functions of n and the lipid acyl chain length.
Reed, Nichole
core   +2 more sources

BET Bromodomain Proteins Are Therapeutic Targets in CRPC [PDF]

Cancer Discovery, 2014
Abstract Small-molecule inhibitors of BET family proteins retard progression of AR-dependent CRPC.
openaire   +1 more source

BET bromodomain proteins [PDF]

Science-Business eXchange, 2014
openaire   +3 more sources

RAPID resistance to BET inhibitors is mediated by FGFR1 in glioblastoma

Scientific Reports
Bromodomain and extra-terminal domain (BET) proteins are therapeutic targets in several cancers including the most common malignant adult brain tumor glioblastoma (GBM). Multiple small molecule inhibitors of BET proteins have been utilized in preclinical
Anna M. Jermakowicz, Alison M. Kurimchak, Katherine J. Johnson, Florence Bourgain-Guglielmetti, Simon Kaeppeli, Maurizio Affer, Hari Pradhyumnan, Robert K. Suter, Winston Walters, Maria Cepero, James S. Duncan, Nagi G. Ayad   +11 more
doaj   +1 more source

A Novel BD2-Selective Inhibitor of BRDs Mitigates ROS Production and OA Pathogenesis

Antioxidants
Bromodomain and extra-terminal domain (BET) family proteins regulate transcription and recognize lysine residues in histones. Selective BET inhibitors targeting one domain have attracted attention because they maintain normal physiological activities ...
Hyemi Lee, Jihye Choe, Min-Hee Son, In-Hyun Lee, Min Ju Lim, Jimin Jeon, Siyoung Yang   +6 more
doaj   +1 more source

Characterizing the Therapeutic Potential of a Potent BET Degrader in Merkel Cell Carcinoma

Neoplasia: An International Journal for Oncology Research, 2019
Studies on the efficacy of small molecule inhibitors in Merkel cell carcinoma (MCC) have been limited and largely inconclusive. In this study, we investigated the therapeutic potential of a potent BET degrader, BETd-246, in the treatment of MCC. We found
Jae Eun Choi, Monique E. Verhaegen, Sahr Yazdani, Rohit Malik, Paul W. Harms, Doris Mangelberger, Jean Tien, Xuhong Cao, Yuping Wang, Marcin Cieślik, Jonathan Gurkan, Mishaal Yazdani, Xiaojun Jing, Kristin Juckette, Fengyun Su, Rui Wang, Bing Zhou, Ingrid J. Apel, Shaomeng Wang, Andrzej A. Dlugosz, Arul M. Chinnaiyan   +20 more
doaj   +1 more source

Targeting BET Proteins Downregulates miR-33a To Promote Synergy with PIM Inhibitors in CMML. [PDF]

Clin Cancer Res, 2023
Letson CT, Balasis ME, Newman H, Binder M, Vedder A, Kinose F, Ball M, Kruer T, Quintana A, Lasho TL, Finke CM, Almada LL, Grants JM, Zhang G, Fernandez-Zapico ME, Gaspar-Maia A, Lancet J, Komrokji R, Haura E, Sallman DA, Reuther GW, Karsan A, Rix U, Patnaik MM, Padron E.   +24 more
europepmc   +1 more source

Mapping genetic interactions in cancer: a road to rational combination therapies. [PDF]

, 2019
The discovery of synthetic lethal interactions between poly (ADP-ribose) polymerase (PARP) inhibitors and BRCA genes, which are involved in homologous recombination, led to the approval of PARP inhibition as a monotherapy for patients with BRCA1/2 ...
Krogan, Nevan J, Tutuncuoglu, Beril
core